authID’s PrivacyKey™ Named “Best Digital Trust Solution - ID Verification & Authentication” in 2025 PayTech Awards

Rhea-AI Summary

Alnylam (Nasdaq: ALNY) reported post hoc analyses from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) showing reductions in gastrointestinal (GI) adverse events and reinforcing monotherapy efficacy.

Key findings: a 42% lower GI event rate overall, 37% lower in vutrisiran monotherapy, and 49% lower in patients on tafamidis at baseline; individual symptoms (diarrhea, nausea, vomiting) fell >50% with rate ratios as low as 0.16. A censored monotherapy analysis showed a 32% reduction in the primary composite endpoint through 36 months (HR 0.68; 95% CI 0.49–0.95; p=0.022), consistent with the primary monotherapy HR 0.67 (p=0.016). AMVUTTRA has >8,000 patient‑years exposure and recent approvals in multiple regions.

Positive

• Overall GI event rate reduced by 42% versus placebo
• Vutrisiran monotherapy GI events reduced by 37%
• Baseline tafamidis group GI events reduced by 49%
• Censored monotherapy: primary endpoint risk ↓ 32% (HR 0.68; p=0.022)
• AMVUTTRA supported by > 8,000 patient‑years exposure

Negative

• AMVUTTRA treatment reduces serum vitamin A; supplementation required
• Common adverse reactions include pain in extremity 15% and arthralgia 11%
• Tafamidis was initiated in 21.5% of monotherapy patients (median ~18 months)

Key Figures

Lower GI event rate (overall): 42% lower rate vs placebo Lower GI event rate (monotherapy): 37% lower rate vs placebo Lower GI event rate (tafamidis baseline): 49% lower rate vs placebo +5 more

8 metrics

Lower GI event rate (overall) 42% lower rate vs placebo HELIOS-B post hoc analysis overall population

Lower GI event rate (monotherapy) 37% lower rate vs placebo HELIOS-B vutrisiran monotherapy group

Lower GI event rate (tafamidis baseline) 49% lower rate vs placebo HELIOS-B baseline tafamidis group

GI symptom reduction >50% reduction Diarrhea, nausea, vomiting across all three study populations

Hazard ratio (primary endpoint) HR 0.68 (95% CI: 0.49–0.95) Censored monotherapy population, all-cause mortality & CV events through 36 months

P-value primary endpoint p=0.022 Risk reduction for all-cause mortality and recurrent CV events

Tafamidis initiation 21.5% of monotherapy patients HELIOS-B censored monotherapy analysis; median 18 months to initiation

Prior HR result HR 0.67 (95% CI: 0.49–0.93); p=0.016 Primary monotherapy analysis including later tafamidis initiators

Market Reality Check

Price: $1.52 Vol: Volume 232,942 is about 0...

low vol

$1.52 Last Close

Volume Volume 232,942 is about 0.06x the 20-day average of 3,632,791, indicating limited trading interest before this award news. low

Technical Shares at $1.23 are trading below the 200-day MA of $4.25 and remain 87.17% under the 52-week high.

Peers on Argus

Sector peers showed mixed moves, with names like CISO up 20.61% and MOGO, USIO, ...

1 Down

Sector peers showed mixed moves, with names like CISO up 20.61% and MOGO, USIO, DVLT modestly positive, while INTZ fell 1.36%. Momentum scanner only flagged BNAI moving down, suggesting today’s modest uptick in AUID is more stock-specific than a broad software rotation.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Customer win	Positive	-2.5%	New deployment of PrivacyKey for biometric security in correctional education.
Nov 24	Equity offering close	Negative	-13.4%	Closing of $3.675M registered direct offering at $1.35–$1.71 per share.
Nov 21	Equity offering pricing	Negative	-21.6%	Pricing of $3.675M registered direct equity and pre-funded warrant deal.
Nov 20	AI partnership	Positive	+5.6%	Joining NVIDIA Connect Program to advance GPU-powered biometric AI security.
Nov 18	Product launch	Positive	-1.8%	Launch of authID Mandate framework for governance of agentic AI identities.

Pattern Detected

Equity offerings have drawn clearly negative reactions, while strategic/AI news shows mixed but sometimes positive alignment with sentiment.

Recent Company History

Over the last month, authID has blended product, AI strategy, and financing news. Two AI-related announcements in November 2025 around the authID Mandate framework and joining the NVIDIA Connect Program produced mixed reactions, including a 5.56% gain. In contrast, the late-November registered direct offering of about $3.675M under an S-3 shelf saw sharp declines of 21.64% and 13.43%. A December selection win in correctional education triggered a small 2.55% pullback, showing that even positive contracts have not consistently lifted the stock.

Market Pulse Summary

This announcement highlights third-party validation of authID’s PrivacyKey™ as a digital trust solut...

Analysis

This announcement highlights third-party validation of authID’s PrivacyKey™ as a digital trust solution, adding to recent product and AI-related developments. Historically, the stock has reacted more strongly to financing events, such as the late-November registered direct offering, than to customer or technology milestones. With shares trading close to the 52-week low and well below the 200-day MA of $4.25, investors may watch for revenue traction, contract wins, and any further capital raises as key follow-ups.

Key Terms

transthyretin-mediated amyloidosis, rnai therapeutic, hazard ratio, confidence interval, +2 more

6 terms

transthyretin-mediated amyloidosis medical

"transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy..."

A progressive disease in which a normally helpful blood protein called transthyretin misfolds and forms sticky clumps (amyloid) that build up in organs, most often the heart and peripheral nerves, impairing their function. It matters to investors because treatments that slow, stop, or reverse those deposits can command significant pricing and long-term demand, so clinical trial results, regulatory decisions, or new competitor drugs can quickly change the commercial outlook—think of it like fixing a widespread plumbing clog that restores flow to critical systems.

rnai therapeutic medical

"AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment..."

An RNAi therapeutic is a medicine that uses small pieces of genetic material to silence a specific gene’s instructions inside cells, like muting one line in a recipe so the dish turns out differently. Investors care because these drugs can target diseases very precisely and, if successful, create new markets or block competitors, but they also carry high technical and regulatory risk around delivery, safety and clinical trial milestones that can strongly move a company’s value.

hazard ratio medical

"reduction... (hazard ratio [HR] 0.68; 95% confidence interval [CI]: 0.49–0.95; p=0.022)."

A hazard ratio is a way scientists compare the chance of something happening over time between two groups, like patients taking different medicines. If the ratio is high, it means one group is more likely to experience the event sooner or more often, which helps determine how effective a treatment is or how risky a situation might be.

confidence interval medical

"hazard ratio [HR] 0.68; 95% confidence interval [CI]: 0.49–0.95; p=0.022"

An interval estimate that shows a range of values within which a true number (like a company’s expected earnings, a projected return, or a model input) is likely to lie, together with a stated level of confidence in that range. For investors it turns a single point forecast into a band—like a weather forecast saying 60–70°F instead of just 65°F—making uncertainty explicit so you can judge risk and size positions more sensibly.

kansas city cardiomyopathy questionnaire medical

"evaluated outcomes by baseline Kansas City Cardiomyopathy Questionnaire overall summary..."

A patient questionnaire that measures symptoms, physical limitations and quality of life for people with heart failure; it gives a standardized score that reflects how the condition affects daily living. Investors care because the score is often used as a clinical-trial endpoint or regulatory evidence to show a treatment actually improves patients’ lives, similar to a customer-satisfaction rating that can influence approval, reimbursement and market uptake.

polyneuropathy medical

"and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults."

Polyneuropathy is a condition in which many nerves outside the brain and spinal cord stop working properly, causing numbness, tingling, weakness or pain in the hands, feet or limbs. Think of it like the electrical wiring in a house developing multiple shorts — it impairs communication and function. For investors, its presence, prevalence or treatment advances can affect demand, regulatory outcomes and the commercial value of drugs, devices or diagnostic tests targeting nerve damage.

AI-generated analysis. Not financial advice.

PrivacyKey™ recognized for delivering fast, secure, privacy-first biometric authentication that enhances trust across digital payments

DENVER, Dec. 10, 2025 (GLOBE NEWSWIRE) -- authID (Nasdaq: AUID), a leading provider of biometric identity verification and authentication solutions, today announced that its flagship product PrivacyKey™ has been named Best Digital Trust Solution – ID Verification & Authentication by Fintech Futures for the 2025 PayTech Awards, which celebrate excellence and innovation in the global payments and fintech industry.

PrivacyKey delivers sub-second, deterministic biometric authentication with a privacy-first approach that ensures users are who they claim to be, while safeguarding sensitive data and meeting global compliance standards. By combining liveness detection, advanced biometric matching, and a patented, privacy-preserving architecture, PrivacyKey enhances security across the entire digital transaction lifecycle.  From account creation and onboarding to payments approvals and ongoing user verification, PrivacyKey offers consumers and enterprises a seamless, fraud-proof experience.

“We are honored that PrivacyKey has been recognized by the PayTech Awards as a leading digital trust solution. At authID, our mission is to eliminate the trade-off between security and convenience by making biometric identity authentication seamless for users and highly effective for enterprises,” said authID CEO Rhon Dauguro. “This recognition validates the impact of PrivacyKey in helping financial institutions and payments providers combat fraud, protect consumers, and strengthen trust. We look forward to continuing to set the standard for secure, frictionless authentication in the payments industry and beyond.”

PrivacyKey features critical key-management capabilities that ensure the highest level of user protection and privacy. Enterprises can rotate and revoke keys with ease, ensuring the keys are accessible only to authorized users, providing a level of security not available through any other vendor. PrivacyKey represents the ultimate in data privacy protection as well as compliance, given that no facial biometrics are stored.

PrivacyKey’s encrypted public keys are minted when users are validated by authID’s Proof^TM solution, the fastest and more accurate biometric IDV platform in the industry. The unique architecture and value of PrivacyKey is the reason it has been chosen by many industry leaders for their identity assurance component. This has led to authID being embedded in technology offered for customers of NEC Networks and System Integration Corporation (NESIC), Prove, and MajorKey, and available in the marketplaces for Zendesk and Nvidia, acting as a critical, easily-integrated option for biometric verification in front of those platforms. PrivacyKey replaces the tokens, facial images, or other vulnerable, device-bound artifacts utilized by other vendors, ensuring privacy protection and industry-leading performance and accuracy.

In addition to its value for human verification, PrivacyKey is a critical part of authID’s IDX platform for securing distributed workforces. It also serves to power the authID Mandate framework for Agentic AI security, by ensuring that AI agents can only be launched after being bound to the credentials of biometrically-verified sponsors, as described in our recent announcement.

“Being named the winner of the Paytech Awards for verification and authentication underscores our commitment to advancing digital trust,” commented Erick Soto, authID’s Chief Product Officer. “We will continue to redefine how enterprises and consumers protect themselves in an increasingly complex threat landscape, while helping organizations build their businesses by onboarding only trusted individuals.”

The full list of 2025 PayTech Award Winners can be found here.

About authID

authID® (Nasdaq: AUID) ensures enterprises “Know Who's Behind the Device™” for every customer or employee login and transaction through its easy-to-integrate, patented, biometric identity platform. authID quickly and accurately verifies a user's identity, eliminating any assumption of 'who' is behind a device to prevent cybercriminals from compromising account openings or taking over accounts. Leveraging a 1-in-1-billion False Positive Rate for the highest level of assurance, coupled with industry-leading speed and privacy-preserving technology, authID provides the most secure digital identity experience. Our IDX platform secures the distributed workforce of employees, contractors, and vendors, as well as bringing authorization and accountability for AI agents through our authID Mandate framework. By creating a biometric root of trust for each user, authID stops fraud at onboarding, detects and stops deepfakes, eliminates password risks and costs, and provides the fastest, frictionless, and most accurate user identity experience in the industry. For more information, please visit www.authID.ai.

authID Investor Relations

investor-relations@authID.ai

FAQ

What did Alnylam (ALNY) report from HELIOS-B on December 10, 2025?

Post hoc HELIOS-B analyses showed reduced GI events and monotherapy benefit for AMVUTTRA, including a 42% overall GI reduction versus placebo.

How much did vutrisiran lower the risk of the primary composite endpoint in monotherapy?

In the censored monotherapy analysis, vutrisiran showed a 32% risk reduction through 36 months (HR 0.68; 95% CI 0.49–0.95; p=0.022).

What GI symptom reductions were reported for AMVUTTRA in HELIOS-B?

Diarrhea, nausea, and vomiting fell >50% across study populations with rate ratios as low as 0.16.

Which safety precaution is required for patients on AMVUTTRA?

AMVUTTRA lowers serum vitamin A; patients should take RDA vitamin A supplementation and see an ophthalmologist for visual symptoms.

Has AMVUTTRA received regulatory approvals and how extensive is clinical experience?

AMVUTTRA has approvals in the US, EU, Japan, UK, Brazil, and UAE and > 8,000 patient‑years of experience worldwide.